February 9, 2021: We agree with FDA scientists that Keytruda is not proven to be effective for women with early stage triple negative breast cancer, but can cause serious health problems.
Read More »Tag: breast cancer
NCHR’s Public Comments on Breast Cancer Treatment for Premenopausal Women
December 7, 2020: We strongly recommend that clinical trials on breast cancer treatments should include pre-menopausal women.
Read More »We can’t ever go to the doctor with our guard down’: Why Black women are 40% more likely to die of breast cancer
Fortune Magazine: June 30, 2020 Black Americans are dying from the COVID-19 pandemic at a disproportionately high rate, and are also much more likely to die from many other health problems. Black women are less likely to develop breast cancer but 40% more likely to die from it than White women. The reasons behind this awful disparity are wide-ranging, and include systemic problems both within healthcare and far beyond it.
Read More »NCHR Comment on FDA’s Draft Guidance on Developing Drugs for Male Breast Cancer
October 28, 2019. Increased diversity and inclusion in clinical trials are important, and we agree with the FDA guidance that male patients with breast cancer should be included in clinical trials.
Read More »Free patient booklet on ductal carcinoma in situ (DCIS)
Our patient booklet, DCIS: What You Need to Know, helps women diagnosed with DCIS understand the difference between DCIS and Stage 1 breast cancer, and discuss treatment options with their doctor. It was funded by a grant from the DC Cancer Consortium through the Department of Health, Government of the District of Columbia, with additional support from the Jacob and Hilda Blaustein Foundation.
Read More »